Cardio3 BioSciences Moves Into Oncology With U.S. Deal

Cardio3 BioSciences SA, a Belgian developer of experimental stem-cell treatments, agreed to buy the OnCyte oncology division of privately held Celdara Medical in the U.S. for $10 million upfront plus potential milestone payments.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.